MedPath

The Study of Atypical Antipsychotics-induced Metabolic Disturbances

Completed
Conditions
Schizophrenia
Antipsychotics
Registration Number
NCT00937755
Lead Sponsor
Taipei Medical University Hospital
Brief Summary

Schizophrenia is one of the most severe mental illnesses. The antipsychotic drugs, introduced in early 1950s, have revolutionized the treatment of schizophrenia. About 2 to 4 times as many patients relapse when treated with a placebo as do those treated with antipsychotic drugs. For these medications to be maximally beneficial, they must have an acceptable side effect profile and be taken as prescribed. One untoward effect of many antipsychotic drugs is weight gain. The extent of weight gain apparently varies by drug, which may be because of drugs'differing degrees of action on serotonergic, dopaminergic, histaminergic, and other neurotransmitter systems. Obesity is a threat to health and longevity. Weight gain may also cause patients taking antipsychotic medication to discontinue their medication, which may predispose them to relapse.

The pattern of weight gain and metabolic disturbance may vary between the different antipsychotic agents. The underlying mechanism and treatment of these adverse metabolic effects remain unclear. This study will recruit 60 schizophrenic patients during. The patients received monotherapy with atypical antipsychotics (olanzapine, quetiapine, or risperidone). The assessment of metabolic profile will be monitored at baseline, week 2, week 4, and week 8. The measurements include anthropometrical parameters, body composition, glucose level, insulin level, lipid profile, and leptin level. Intra-venous glucose tolerance test will be used to assess the insulin secretion and insulin sensitivity.

This proposal broadly aims to discover the underlying mechanism of antipsychotics induced metabolic disturbance and develop efficient treatment to correct it.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • clinical diagnosis of schizophrenia
  • age 18-60 years
Exclusion Criteria
  • received any SGAs prior to this study
  • medical conditions that may confound glucoregulatory assessment
  • pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
glucose homeostasis8 weeks
Secondary Outcome Measures
NameTimeMethod
lipid homeostasis8 weeks

Trial Locations

Locations (1)

Taipei Medical University-Municipal Wan-Fang Hospital

🇨🇳

Taipei, Taiwan

Taipei Medical University-Municipal Wan-Fang Hospital
🇨🇳Taipei, Taiwan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.